HOIL: Molecular Composition, Deficiency, and Immune Impact

HOIL-1 is a protein that sits at a crossroads between immune defense and basic cellular housekeeping. As one of three components in a molecular machine called LUBAC, it helps build a specialized type of ubiquitin chain that switches on inflammatory signaling. Lose HOIL-1 and the consequences are paradoxical: patients develop both a weakened immune response to bacteria and runaway auto-inflammation, alongside a buildup of toxic glycogen deposits in the heart, muscles, and brain. Understanding why one protein’s absence produces such a strange combination of problems requires looking at what HOIL-1 actually does at the molecular level.

How HOIL-1 Fits Into the LUBAC Complex

LUBAC, short for Linear Ubiquitin Chain Assembly Complex, is built from three proteins: HOIL-1L (often just called HOIL-1), HOIP, and SHARPIN. Each brings a different capability to the partnership, but the complex only works properly when all three are present and properly assembled. HOIP is the catalytic engine that forges the distinctive head-to-tail (Met1-linked) ubiquitin chains LUBAC is known for. SHARPIN helps stabilize the complex and recruit it to the right signaling platforms. HOIL-1 contributes its own enzymatic activity and plays a structural role that keeps the whole assembly together.

Crystallography work revealed how HOIL-1 and SHARPIN physically lock onto each other. Each protein contains a short stretch of amino acids near its front end that folds into a helix-helix-strand motif. These stretches, termed LUBAC-tethering motifs, pair up and merge into a single compact structure called the tethering domain. That merged domain is remarkably resistant to being pulled apart, which explains why LUBAC holds together as a stable unit rather than falling apart after each round of signaling.

¹ The tethering domain is not just glue, though. Without it, the three-way partnership between HOIL-1, SHARPIN, and HOIP destabilizes, and LUBAC’s ability to generate linear ubiquitin chains drops sharply.

An Enzyme That Breaks the Rules

For years, HOIL-1’s enzymatic activity was overshadowed by HOIP’s chain-building power. Researchers knew HOIL-1 carried the hallmarks of an E3 ubiquitin ligase, but its catalytic contribution to LUBAC was unclear. That picture changed when studies showed that HOIL-1 catalyzes an unusual chemical reaction: instead of attaching ubiquitin to other proteins through the typical bond between ubiquitin and a lysine side chain, HOIL-1 links ubiquitin to serine and threonine residues through an oxyester bond.

This distinction matters because oxyester bonds are chemically different from the standard isopeptide bonds used by most ubiquitin ligases. They are more labile, meaning the cell can reverse them more easily. HOIL-1 is a monoubiquitylating enzyme: it attaches a single ubiquitin molecule to its targets, which can then serve as a seed for longer ubiquitin chains to be assembled by HOIP or other enzymes. Targets include components of the Myddosome, a signaling scaffold that activates innate immune pathways, and HOIL-1 even monoubiquitylates itself and its partner SHARPIN in living cells. The ester-linked ubiquitin that HOIL-1 installs appears to be critical for properly shaping the ubiquitin landscape around active signaling complexes, ensuring that linear chains form where they are needed.

Switching On the NF-κB Pathway

The primary signaling job of LUBAC, and by extension HOIL-1, is activating the NF-κB pathway. NF-κB is a master regulator of inflammation and immune cell survival. When a cell detects a pathogen or receives a pro-inflammatory signal, a cascade of events converges on a gatekeeper protein called NEMO. LUBAC attaches Met1-linked linear ubiquitin chains to NEMO and to a signaling adaptor called RIP1, and these chains serve as a scaffold that brings the right kinases into position to unleash NF-κB into the nucleus, where it turns on hundreds of genes involved in fighting infection, preventing premature cell death, and coordinating the inflammatory response.

⁴

When any LUBAC component is missing, NF-κB signaling weakens. That weakening has two consequences that seem contradictory but stem from the same root. First, immune cells become less able to mount effective responses against bacteria, leaving the body vulnerable to pyogenic (pus-forming) infections. Second, the weakened NF-κB signal fails to suppress certain cell-death pathways, leading cells to die in inflammatory ways that trigger tissue damage and chronic inflammation. The same molecular deficit produces both too little immunity where you need it and too much inflammation where you don’t.

Built-In Brakes on the Signal

Immune activation cannot run unchecked, and the cell has a clever feedback mechanism that uses HOIL-1 cleavage as an off switch. When T cells or B cells receive strong activation signals, a protease called MALT1 cuts HOIL-1 roughly in half.

⁵ The cleavage fragment that remains stuck in LUBAC acts as a dominant-negative inhibitor: it occupies HOIL-1’s slot but lacks the catalytic machinery to do HOIL-1’s job. The result is that linear ubiquitination at the signaling complex drops, and NF-κB activation tapers off.

Work in B cells mapped this feedback loop in detail. Early in the activation cycle, MALT1 acts as a positive regulator, helping to assemble the signaling scaffold that recruits LUBAC. But late in the cycle, MALT1 switches roles and cleaves HOIL-1, transiently reducing linear ubiquitination of NEMO and RIP1. This dampens NF-κB and prevents the cell from being reactivated too quickly.

⁶ MALT1 is therefore both the accelerator and the brake, first promoting NF-κB activation through one mechanism and then shutting it down through HOIL-1 destruction. This dual role explains why drugs targeting MALT1 in cancer and autoimmunity need to be calibrated carefully: block MALT1 completely and you lose both functions.

What Happens When HOIL-1 Is Missing

Only a handful of patients with inherited HOIL-1 deficiency have been identified, but their clinical picture is striking. The first detailed report described three patients from two unrelated families carrying loss-of-function mutations in the RBCK1 gene, which encodes HOIL-1. These patients displayed a paradoxical combination of auto-inflammatory disease and increased vulnerability to pyogenic bacterial infections, a pairing almost unheard of in other inborn errors of immunity.

⁷

On the infection side, patients struggled with invasive bacterial diseases caused by common pyogenic organisms. Their immune cells, deprived of functional LUBAC, could not mount a full NF-κB response when encountering pathogens. On the inflammation side, tissues showed signs of chronic, sterile inflammation driven by cell-death pathways that NF-κB would normally keep in check. Gut involvement has been prominent: HOIL-1-deficient patients commonly experience chronic intestinal inflammation and diarrhea.

⁸

But the most unexpected feature of HOIL-1 deficiency is muscular amylopectinosis: the accumulation of abnormal, poorly branched glycogen deposits (polyglucosan bodies) inside cells of the heart, skeletal muscle, and other tissues. These deposits had never been associated with an immunodeficiency before. Over time, they contribute to progressive myopathy and cardiomyopathy that can be life-threatening. A more recently described patient carried a homozygous frameshift variant in RBCK1 and presented primarily with dilated cardiomyopathy and muscle weakness, reinforcing the cardiac and muscular dimensions of the disease.

⁹

Why an Immune Protein Controls Glycogen

The connection between HOIL-1 and glycogen storage disease puzzled researchers for years. The breakthrough came when studies showed that HOIL-1’s E3 ligase activity directly targets sugars, not just proteins. Mice engineered to express a catalytically dead version of HOIL-1 (the C458S mutant) accumulated polyglucosan in the brain, heart, and other organs, confirming that HOIL-1’s enzymatic activity is essential for preventing these toxic deposits.

¹⁰

In the test tube, HOIL-1 monoubiquitylates glycogen and short unbranched sugar chains (maltoheptaose), attaching ubiquitin through an ester bond to the C6 hydroxyl group of glucose. This reaction was dramatically accelerated when linear or Lys63-linked ubiquitin oligomers were present, boosting the rate more than a hundredfold. HOIL-1 could even transfer preformed ubiquitin oligomers onto the sugar chain in a single catalytic step.

¹¹

The leading hypothesis is that by tagging unbranched glucosaccharides with ubiquitin, HOIL-1 marks them for disposal through a selective autophagy pathway called glycophagy. Normally, glycogen molecules that lose their proper branching structure risk precipitating out of solution as insoluble polyglucosan. HOIL-1’s ubiquitin tag would recruit the autophagy machinery before that happens, clearing the abnormal sugar before it can form a toxic deposit. Without HOIL-1, unbranched glycogen intermediates escape this quality-control step and slowly accumulate as polyglucosan bodies, particularly in metabolically active tissues like the heart and brain.

Mouse brains deficient in HOIL-1 showed heavy polyglucosan accumulation in the hippocampus, cerebellum, and spinal cord, with total brain glycogen levels significantly elevated.

¹² The same study found that reducing glycogen synthase activity could rescue the polyglucosan accumulation, confirming that the problem begins upstream, at the point where glycogen is being made and not properly cleared.

Gaps Between Mouse Models and Human Disease

Animal models of HOIL-1 deficiency reproduce some features of the human disease but not others, and the discrepancies highlight aspects of the biology that remain unclear. Both HOIL-1 knockout mice and HOIL-1-deficient patients develop amylopectinosis, so the glycogen clearance function appears to be conserved across species. But the severe myopathy and cardiomyopathy seen in patients are not prominent in the mice.

¹³

Researchers used human stem cells from patients to try to bridge this gap. Heart muscle cells grown from patient-derived stem cells were abnormally large and excessively multinucleated compared with controls, and muscle tube cells differentiated from HOIL-1-knockout mouse cells showed impaired maturation with accumulation of cells stuck in the wrong stage of the cell cycle.

¹⁴ These findings suggest that HOIL-1 plays a role in muscle cell maturation beyond its glycogen clearance function. The muscle and heart problems in patients may not be purely a consequence of glycogen dumping; HOIL-1 loss may also impair normal muscle development at a cellular level, a feature that short-term cell culture and mouse lifespans do not fully capture.

This divergence between species is a recurring theme in rare immunodeficiency research. Mice live roughly two years, develop disease more slowly, and have somewhat different immune cell compositions and cardiac physiology. For HOIL-1 deficiency, the mouse provides a solid model for understanding the polyglucosan pathway but a less reliable one for predicting the severity of cardiac and skeletal muscle disease in humans.

Gut Immunity and Bacterial Susceptibility

Among the most clinically relevant consequences of HOIL-1 loss is compromised intestinal defense. HOIL-1 regulates group 3 innate lymphoid cells (ILC3s) in the colon, a population of immune cells that produce cytokines critical for maintaining the gut barrier and fighting off enteric bacteria. In mouse models, HOIL-1 deficiency led to reduced ILC3 numbers in the colon, colonic ulceration, systemic bacterial dissemination, and lethality following infection with an intestinal pathogen.

⁸

This fits with the clinical picture in patients, who experience chronic diarrhea and intestinal inflammation along with susceptibility to invasive bacteria. The gut is a frontline barrier between the body and an enormous microbial load, and the NF-κB pathway is central to how the gut epithelium and resident immune cells coordinate their defense. When LUBAC cannot signal effectively because HOIL-1 is absent, the gut barrier weakens, inflammatory cell death damages the lining, and bacteria that would normally be contained gain access to deeper tissues. The combination of barrier breakdown and impaired immune killing creates a double vulnerability that makes these patients prone to severe, sometimes life-threatening infections.

LUBAC’s Role in Lymphoma

The same NF-κB signaling that LUBAC activates in healthy immune cells can be hijacked by cancer. A subtype of diffuse large B-cell lymphoma known as activated B-cell type (ABC DLBCL) depends on constitutive NF-κB activity for survival. When researchers depleted HOIP or SHARPIN from ABC DLBCL cell lines using RNA interference, the cancer cells died, while a related but molecularly distinct subtype (germinal center B-cell DLBCL) was largely unaffected.

¹⁵

This selective dependency makes LUBAC an attractive therapeutic target in ABC DLBCL. Because HOIL-1 is required for LUBAC stability and its monoubiquitylation activity primes the signaling platforms that HOIP then extends with linear chains, disrupting HOIL-1’s function could theoretically collapse the whole LUBAC-dependent NF-κB signal in these tumors. The challenge, of course, is specificity. Healthy immune cells also need LUBAC, and the glycogen-clearance function of HOIL-1 means that systemic inhibition could produce the same polyglucosan accumulation and immune dysfunction seen in deficient patients. Any therapeutic strategy targeting LUBAC in cancer would need to be delivered precisely to tumor cells while sparing normal tissues, a problem common to many targeted therapies but especially stark here given the breadth of HOIL-1’s biological roles.

HOIL-1 and Oxyester Ubiquitination as a Broader Signaling Mechanism

The discovery that HOIL-1 uses ester bonds rather than the conventional isopeptide linkage to attach ubiquitin opened a new chapter in ubiquitin biology. Before HOIL-1’s activity was characterized, oxyester-linked ubiquitination was essentially unknown as an intracellular signaling mechanism in mammals. The finding that this chemistry is used both on protein substrates (serine and threonine residues on signaling adaptors) and on sugar substrates (the hydroxyl group on glucose) suggests a versatility that researchers are still mapping.

Because ester bonds are more easily reversed than isopeptide bonds, they may serve as rapid, transient signals that the cell can install and remove on a faster timescale. In immune signaling, where activation must be switched on quickly and then shut down before it causes collateral damage, a chemically labile ubiquitin tag fits the need for speed and reversibility. The MALT1-mediated cleavage of HOIL-1 adds another layer of temporal control: even the enzyme producing these transient tags can itself be destroyed mid-signal. The result is a signaling system with multiple built-in timers, each set to go off at a different point in the activation cycle.

Whether other E3 ligases in the cell use similar oxyester chemistry remains an open question. HOIL-1 was the first clear example, and its unusual activity was missed for years because the ester bond is sensitive to standard biochemical conditions that would preserve an isopeptide bond. Protocols that use alkaline treatment to strip ubiquitin from substrates, for instance, would have destroyed HOIL-1’s ester-linked products without anyone noticing. This technical blind spot raises the possibility that ester-linked ubiquitination is more widespread than currently appreciated and has simply been invisible to the methods researchers were using.